Hematologic malignancies are one of the most common cancers, and the incidence has
been rising in recent decades. The clinical and molecular features of hematologic …

Cancer is a global public health concern. Alterations in epigenetic processes are among the
earliest genomic aberrations occurring during cancer development and are closely related …

Background Although induction chemotherapy results in remission in many older patients
with acute myeloid leukemia (AML), relapse is common and overall survival is poor …

We undertook a comprehensive proteogenomic characterization of 95 prospectively
collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This …

Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR)
T cells is hampered by toxicity on normal hematopoietic progenitor cells and low CAR T cell …

Purpose: Patients with acute myeloid leukemia (AML) frequently do not respond to
conventional therapies. Leukemic cell survival and treatment resistance have been …

The DNA methyltransferase (DNMT) inhibitors azacytidine and decitabine are the most
successful epigenetic drugs to date and are still the most widely used as epigenetic …

Abstract Epigenetic (“above genetics”) modifications can alter the gene expression without
altering the DNA sequence. Aberrant epigenetic regulations in cancer include DNA …

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute
myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible …

Patterns of DNA methylation are established during embryonic development and faithfully
copied through somatic cell divisions. Based on current understanding of DNA methylation …